Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MedTech-related health technology assessments from NIHR in April 2022

27 May 2022

The National Institute for Health Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance.

In April 2022, two MedTech-related assessments were published in the NIHR HTA Journal:

  • An assessment of uterine artery embolization versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy was based on a multicenter, open, randomized trial with a parallel economic evaluation (FEMME). The study was carried out in 29 UK hospitals. It was concluded that myomectomy resulted in greater improvement in quality of life at two years compared with uterine artery embolization for women with uterine fibroids and at a lower cost. However, the differences in costs and quality-adjusted life years are very small. Future research should involve women who desire pregnancy;
  • An assessment of supraglottic airway device versus tracheal intubation in the initial airway management of out-of-hospital cardiac arrest was based on a pragmatic, open, parallel, two-group, multicenter, cluster randomized controlled trial (AIRWAYS-2) and cost-effectiveness analysis. The settings were four ambulance services. There was no difference in favorable functional outcome at 30 days or hospital discharge between initial advanced airway management with a supraglottic airway device or tracheal intubation. There were no notable differences in costs, outcomes, and overall cost-effectiveness between the groups.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).